Literature DB >> 21135852

Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine.

Gary J Nabel1, Anthony S Fauci.   

Abstract

The immune system normally responds to influenza virus by making neutralizing antibodies to regions of the viral spike, the hemagglutinin, that vary year to year. This natural response protects against circulating subtypes but necessitates production of new vaccines annually. Newer vaccine approaches have succeeded in eliciting broadly neutralizing antibodies to highly conserved yet vulnerable regions of the hemagglutinin and suggest potential pathways for the development of universal influenza vaccines.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21135852     DOI： 10.1038/nm1210-1389

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  19 in total

1.  Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Authors:  Chih-Jen Wei; Jeffrey C Boyington; Patrick M McTamney; Wing-Pui Kong; Melissa B Pearce; Ling Xu; Hanne Andersen; Srinivas Rao; Terrence M Tumpey; Zhi-Yong Yang; Gary J Nabel
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

Review 4.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

5.  Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Authors:  Srinivas S Rao; Wing-Pui Kong; Chih-Jen Wei; Neal Van Hoeven; J Patrick Gorres; Martha Nason; Hanne Andersen; Terrence M Tumpey; Gary J Nabel
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

6.  Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Authors:  John Steel; Anice C Lowen; Taia T Wang; Mark Yondola; Qinshan Gao; Kester Haye; Adolfo García-Sastre; Peter Palese
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

Review 7.  Pandemic preparedness: toward a universal influenza vaccine.

Authors:  Kenny Roose; Walter Fiers; Xavier Saelens
Journal:  Drug News Perspect       Date:  2009-03

8.  INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

Authors:  J L SCHULMAN; E D KILBOURNE
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

9.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

10.  Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion.

Authors:  Rupert J Russell; Philip S Kerry; David J Stevens; David A Steinhauer; Stephen R Martin; Steven J Gamblin; John J Skehel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205
View more
  85 in total

1.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

2.  Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Authors:  Shin Murakami; Taisuke Horimoto; Mutsumi Ito; Ryo Takano; Hiroaki Katsura; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

3.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

4.  Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity.

Authors:  José V Pérez-Girón; Alan Belicha-Villanueva; Ebrahim Hassan; Sergio Gómez-Medina; Jazmina L G Cruz; Anja Lüdtke; Paula Ruibal; Randy A Albrecht; Adolfo García-Sastre; César Muñoz-Fontela
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

5.  A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Authors:  Ryuta Uraki; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Satoshi Fukuyama; Emi Takashita; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

6.  Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.

Authors:  Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

7.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

Review 8.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

Review 9.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

10.  Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.

Authors:  Michael R Yeaman; Scott G Filler; Siyang Chaili; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John P Hennessey; Yue Fu; Clint S Schmidt; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.